Accrol Group Holdings plc is a leading independent tissue converter, manufacturing toilet rolls, kitchen rolls, facial tissues and AFH products to supply retailers throughout the UK. Accrol imports parent reels from around the world and converts them into finished goods at the Company’s 350,000 sq. ft. manufacturing, storage and distribution facility in Blackburn, Lancashire. Accrol currently manufactures approximately 17 million units per week and supplies some of the UK’s largest retailers.

Accrol Group Holdings plc is listed on AIM, the growth market of the London Stock Exchange.

The Company was incorporated and registered in England and Wales on 30 April 2014 under the Act with registered number 9019496 as a private company limited by shares with the name Aghoco 1220 Limited. The name of the Company was changed to Accrol Group Holdings Limited on 1 August 2014. The Company was re-registered as a public limited company with the name Accrol Group Holdings plc on 1st June 2016. Accrol Group Holdings plc’s main country of operation is the UK.

The Company, and the Group, trade under the name “Accrol Papers”.

New high.:-))

And in my opinion with plenty more to go, can't call it but even at this level will be a multi-bagger.

Was hoping it would fall to stock up on more and if it does I most certainly will

All good for me glad I got in at the IPO should have got more then, but then isn't that always the way when you have a good one

Good to hear from you Stevesham. I'm up 16% now. :-)) This will move with the installation of the new machine/ machines and any announcements at the agm.

Hi Dreamcatcher love your posts, and yes this is a good solid one for pure growth I so need to buy more when prudent to do so

16% for me too, which if I am right is only the tip of the iceberg

I think if it drops below £1.20 I could be quite easily tempted to get more, however I really can only see this going one way and that is up!

Bought more today Stevesham, sitting on a good holding now.

Nice 300,000 @ 130p


http://www.moneyam.com/trades/ACRL

Excellent, and congratulations on your new purchase! I am so tempted for more.....

They will head towards 200p perhaps by the new year or early part of.

RNS Number : 2527L
Accrol Group Holdings PLC
29 September 2016
 
This announcement contains inside information
 
Accrol Group Holdings plc (the "Company" or "Accrol")
 
Director's Dealing
 
Accrol Group Holdings plc, the AIM listed leading independent tissue converter, is pleased to announce that is has been notified that Stephen Crossley, CEO of Accrol, has purchased 100,000 ordinary shares of £0.001 each ("Ordinary Shares") via his SIPP on 29th September 2016 at a price of 132p per Ordinary Share.

Following this transaction, Stephen has an interest in 100,000 Ordinary Shares, representing approximately 0.1 per cent. of the Company's issued Ordinary Share capital.
 
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

A £132 grand spend by the CEO shows confidence. Lets hope for a good future.

AGM -NOTICE IS GIVEN that the Annual General Meeting of Accrol Group Holdings plc will be held at Stanley House Hotel, Mellor, Lancashire BB2 7NP on 30 September 2016 at 11am for the following purposes:

AGM notes

New high. :-))

Accrol general meeting. some good warehouse pictures


Next Event
30/04/2017
Next year end (to be reported)

Good large 25,000 and 100,000 buys. On the way now.


http://www.moneyam.com/trades/ACRL

Indeed well on the way and it's not going to drop to my target to buy more at £1.20, this I think will easily double.

Going to look at any dips (I doubt there will be any) and top up, better to average up than average down!

DYOR GLA :-)

ST of IC today - When a director splashes out over £100,000 buying shares in his company it’s always worth further investigation. I didn’t have to do much research in the case of Accrol (ARCL:140p), the Aim-traded Blackburn-based maker of toilet rolls, kitchen rolls and facial tissues, as this is a business I know well, having recommended buying the shares when they floated at 100p in the summer ('Clean up with Accrol', 6 Jun 2016), and subsequently reiterated that advice at 118p (‘Brexit winners’, 1 Aug 2016).
The fact that chief executive Stephen Crossley has just invested £132,000 of his own money buying 100,000 shares at a 32 per cent premium to the float price tells a story about Accrol’s trading prospects. Higher consumer demand for private-label products is helping drive ongoing strong sales growth from discount retailers, a segment where the company has a 35 per cent market share, as is management’s ability to cross sell multiple products to new clients. Maiden results have done nothing to alter my earlier positive stance: like-for-like sales rose by 17 per cent to £118m in the year to end April 2016, and analyst Mike Allen at house broker Zeus Capital expects Accrol to maintain this heady growth rate in the current financial year, pencilling in revenue of £138m.
On this basis, expect cash profits to rise by around 10 per cent to £16.4m to produce pre-tax profits of £13.4m and EPS of 11.5p in the 12 months to end April 2017. This means Accrol’s shares are being valued on a forward PE ratio of 12, a rating that fails to acknowledge its potential to continue to grow earnings at a double digit rate for years to come. Indeed, for the following year to end April 2018, Mr Allen believes that Accrol can lift revenues to £156m, increase both cash profits and pre-tax profits by £2.2m, and deliver EPS of 13.4p to reduce the forward PE ratio to 10.5. I am comfortable with those estimates.
The current rating also fails to fully reflect the company’s cash generation. Indeed, net debt is expected to fall to £16m by end April 2017, a sum equivalent to one times cash profits and less than 30 per cent of shareholders funds. So, with profits growing strongly, and the balance sheet modestly geared, the board can recycle cashflow into a progressive dividend. Guidance is for a 6p a share payout in the current year, implying the shares offer a 4.4 per cent prospective dividend yield, rising to around 6.25p a share the year after.
In the circumstances, it’s hardly surprising my 130p target price has proved too conservative and I now feel that a rating of 12 times EPS estimates of 13.4p for the 12 months to end April 2018 is a more realistic valuation. This implies a new target price of 160p, and one that more accurately takes into account Accrol’s low balance sheet gearing, and prospects of delivering double digit earnings growth. Buy.

Details of dividend below -



EVENT
TIMING
RECENT/UPCOMING DATES
Financial year
Year end 30 April
Half year end 31 October

Results published
Full year preliminary results
Our preliminary results for the year ending 30 April 2016 were released on 22 July 2016. These are available on the ‘Company Reports and Presentations’ page and in the ‘Regulatory News’ section of our website.

Interim results
Our interim results for the half year ending 31 October 2016 will be released mid-January 2017.
AGM
Late September
Our 2016 AGM was held on 30 September 2016 at 11am at Stanley House Hotel, Mellor. The AGM Result can be found on the ‘Regulatory News’ section of our website.
Dividends
Interim dividend record date November, paid January
An interim dividend of 1/3 is expected to be paid in January 2017.

Final dividend record date May, paid September (subject to shareholder approval).
A final dividend of 2/3 per share for the year ending 30 April 2017 is expected to be paid September 2017.

Shorting activity = very low


On Thursday, Accrol Group Holdings PLC (ACRL:LSE) closed at 121.50, -13.83% below its 52-week high of 141.00, set on Oct 11, 2016.

Pre-close trading statement
RNS
RNS Number : 4344O
Accrol Group Holdings PLC
07 November 2016
 
This announcement contains inside information
7 November 2016
 
Accrol Group Holdings plc ("Accrol" or "the Company")
Pre-close trading statement
 
Accrol Group Holdings plc, the AIM listed leading independent tissue converter, is pleased to provide the following update on trading.   
The business has made good progress since the start of this financial year and trading has been in line with our expectations. During the six months ended 31 October 2016, the Company has continued to win new business with existing customers in addition to the previously announced new £10m contract gain, which we can now confirm is Lidl.
Installation of two high-speed converting lines in our new 168,000 sq. ft. manufacturing facility in Leyland is well underway and will increase our total capacity to 143,000 tonnes per annum. The premises will initially house the two high speed tissue converting lines we purchased in April 2016 and the increased capacity will support our continued growth with both Discounters and Major Multiples in the UK.
We continue to follow our hedging policy to mitigate adverse movements in Sterling against the US$ and Euro. Following our significant purchase of dollars pre-Brexit, we have increased our facilities and we continue to closely monitor the Company's forward currency positions.
We remain confident in the outlook for the full year and that the strong cash flows generated by the business will support our progressive dividend policy and underpin our continued growth.
The Company's interim results will be announced on Thursday 5th January, 2017.
Steve Crossley, Accrol's CEO, commented:
 
"Since the start of this financial year we have made good progress on our strategic aims and we are increasing our production capacity to enable us to take advantage of new opportunities as they arise.
 
"We are pleased with the new business that we have won since the start of the financial year and with progress on the manufacturing facility in Leyland, Lancashire and look forward to the future with confidence."
 
Ends

ST of IC - And as I pointed out when I first recommended buying the shares when they floated at 100p in the summer ('Clean up with Accrol', 6 Jun 2016), the company has reported compound annual sales growth of 16 per cent over the past four years, and profitably, too. Cash profit increased by 14 per cent in the period to £15m in the 12 months to the end of April 2016, and analysts expect a rise to £16.4m in the current financial year to produce pre-tax profit of £13.4m, EPS of 11.5p and support a dividend of 6p a share. On that basis, the shares are rated on 11 times earnings estimates, and offer a prospective dividend yield of 4.7 per cent, hardly an exacting rating for a company that has a track record of delivering double-digit profit growth and one targeted at the high growth discount sector. Indeed, Aldi and Lidl now have over 10 per cent of the UK retail market and are opening five times as many new stores as all their 'Big Four' rivals combined, so expect them to make further market share gains in the coming years.
So, having raised my target price to 160p when I last rated the shares a buy at 140p ('High fives', 4 Oct 2016), I have no hesitation reiterating that advice. Buy.